32 completed, 31 recruiting, 16 unknown, 12 not yet recruiting. 114 Phase 2, 24 Phase 1, 2 Phase 3.
Follow Advanced Breast Cancer: new trials by email Literature Review of Advanced Breast Cancer trials Research Report on Advanced Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer Trastuzumab deruxtecan, Lovastatin - Breast Cancer, Advanced Breast Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 60 | 2026-10-31 | 2026-09-22 |
| A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations. Zongertinib (BI 1810631), Fulvestrant - Advanced Breast Cancer, Hormone Receptor Positive / HER2-negative Breast Cancer | Phase 2 | Not yet recruiting | MedSIR | 25 | 2026-10-04 | 2026-06-01 |
| Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer Trastuzumab Rezetecan, Pyrotinib, trastuzumab - HER2 + Breast Cancer, Advanced Breast Cancer | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 50 | 2026-09-30 | 2026-08-14 |
| Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study Paclitaxel Oral Solution (50mg/qd), Paclitaxel Oral Solution (100mg/TIW), Paclitaxel Oral Solution (OTD) - Advanced Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 73 | 2026-08-04 | 2026-08-11 |
| A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer AK146D1 for injection, AK112 Injection - Advanced Breast Cancer | Phase 2 | Recruiting | Akeso | 200 | 2026-07-17 | 2026-07-22 |
| Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients SHR-A1811 - HER2positive, Advanced Breast Cancer | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 60 | 2026-06-10 | 2026-06-11 |
| Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer Trastuzumab Rezetecan for Injection (SHR-A1811), Trastuzumab Deruxtecan for Injection (T-DXd) - Advanced Breast Cancer | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 100 | 2026-06-01 | 2026-06-05 |
| A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer SYS6023, KN026 - Advanced Breast Cancer | Phase 2 | Recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 36 | 2026-05-25 | 2026-06-16 |
| Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer Camizestrant, Atirmociclib - Advanced Breast Cancer | Phase 2 | Recruiting | AstraZeneca | 24 | 2026-05-06 | 2026-09-29 |
| Phase II, Prospective, Randomized, Proof-of-concept Study to Evaluate the Effects of a Personalized Dietary Intervention in Women With Advanced Gynecologic or Breast Tumors Treated With Antibody-Drug Conjugates (ADCs). Personalised dietary intervention., General recommendations - Gynecologic Cancers, Advanced Breast Cancer | Phase 2 | Recruiting | TNC Nutrición Terapéutica S.L. | 100 | 2026-03-10 | 2026-10-08 |
| A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer Toripalimab, TPC - Advanced Breast Cancer | Phase 2 | Recruiting | Henan Cancer Hospital | 92 | 2026-01-20 | 2026-04-20 |
| Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers Biological samples collection, questionnaires to collect patient reported outcomes - Advanced Breast Cancer, Advanced Gastric Cancer | Phase 2 | Recruiting | UNICANCER | 400 | 2025-11-14 | 2025-12-02 |
| SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer SHR2554, HRS-8080 - Advanced Breast Cancer | Phase 2 | Recruiting | Henan Cancer Hospital | 30 | 2025-10-14 | 2026-10-15 |
| A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors MHB036C for Injection, MHB039A for Injection - Advanced Breast Cancer, Advanced Malignant Solid Tumor | Phase 2 | Recruiting | Minghui Pharmaceutical (Hangzhou) Ltd | 210 | 2025-09-30 | 2026-10-09 |
| Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer QL1706, CDK4/6 inhibitor, Fulvestrant - Advanced Breast Cancer | Phase 2 | Recruiting | Wenjin Yin | 123 | 2025-09-25 | 2025-11-18 |
| A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer QLC1401 - Advanced Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 96 | 2025-09-01 | 2025-09-15 |
| Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer Pyrotinib - Advanced Breast Cancer | Phase 2 | Recruiting | Wenjin Yin | 186 | 2025-08-28 | 2025-11-18 |
| Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer Trastuzumab rezetecan + CDK4/6 inhibitors + endocrine therapy - Advanced Breast Cancer | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 45 | 2025-08-18 | 2025-12-31 |
| A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer HB1801, Taxotere® - Advanced Breast Cancer | Phase 2 | Not yet recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 60 | 2025-08-15 | 2025-07-24 |
| Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype Trastuzumab deruxtecan (T-DXd, DS-8201a), CDK4/6i plus ET - Advanced Breast Cancer, Advanced Breast Carcinoma | Phase 2 | Recruiting | MedSIR | 200 | 2025-06-30 | 2026-07-30 |
Showing 20 of 114. Sign in to see all of them.
Breast Neoplasms (49) · Neoplasms (8) · Triple Negative Breast Neoplasms (6) · Brain Neoplasms (3) · Neoplasm Metastasis (3) · Ovarian Neoplasms (2) · Anxiety Disorders (1) · Breast Diseases (1) · Breast Neoplasms, Male (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Head and Neck Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1)
Neoplasms by Site (50) · Skin Diseases (50) · Skin and Connective Tissue Diseases (50) · Breast Diseases (49) · Neoplasms (45) · Nervous System Diseases (4) · Brain Diseases (3) · Central Nervous System Diseases (3) · Central Nervous System Neoplasms (3) · Genital Diseases (3) · Neoplastic Processes (3) · Nervous System Neoplasms (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Urogenital Diseases (3)
Fulvestrant (20) · Capecitabine (9) · Trastuzumab (8) · Letrozole (6) · trastuzumab deruxtecan (6) · Everolimus (5) · Goserelin (5) · neratinib (5) · olaparib (5) · sacituzumab govitecan (5) · talazoparib (5) · Injections (4) · Paclitaxel (4) · eribulin (4) · exemestane (4)
MedSIR (11) · Fudan University (6) · AstraZeneca (5) · Novartis Pharmaceuticals (4) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (4) · Henan Cancer Hospital (3) · Puma Biotechnology, Inc. (3) · Seoul National University Hospital (3) · The First Affiliated Hospital with Nanjing Medical University (3) · Fuda Cancer Hospital, Guangzhou (2) · Fujian Medical University Union Hospital (2) · Gustave Roussy, Cancer Campus, Grand Paris (2) · Neovii Biotech (2) · Pfizer (2) · Spanish Breast Cancer Research Group (2)
China (46) · United States (30) · Spain (18) · France (12) · United Kingdom (12) · Italy (11) · Canada (8) · Belgium (7) · South Korea (7) · Germany (6) · Poland (6) · Japan (5) · Australia (4) · Czechia (4) · Hungary (4)
Min Yan, Chief physician (2) · Wenjin Yin, M.D. (2) · Adam Ostrowski, MD (1) · Agnes Jager, MD, PhD (1) · Alice P Chen, M.D. (1) · Alicia Okines (1) · Andrew A Davis, MD (1) · Antonio Llombart, PhD (1) · Antonio Llombart-Cussac (1) · Antonio Llombart-Cussac, MD (1)
PMID 20632084, PMID 21931708, PMID 23632474, PMID 23801303, PMID 23953056, PMID 24674873, PMID 28228842, PMID 28314691, PMID 28445973, PMID 28650446, PMID 30792217, PMID 31194225, PMID 31194228, PMID 32043762, PMID 32193378, PMID 32390277, PMID 32919527, PMID 33084020, PMID 33591468, PMID 33763756, PMID 33893289, PMID 34037241, PMID 34771596, PMID 36253484, PMID 36463104, PMID 38010394, PMID 38904918, PMID 38940019, PMID 38969879, PMID 39229468, PMID 39255534, PMID 39265579, PMID 39680411, PMID 40013319, PMID 40294349, PMID 40467896, PMID 40525978, PMID 40908353, PMID 41016944, PMID 41063198, PMID 42481711
2023 (3), 2016 (2), 2018 (2), 2019 (2), 2005 (1), 2017 (1)